CoChat

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases

Open access
Haile, Pamela A., Casillas, Linda N., Votta, Bartholomew J., Wang, Gren Z., Charnley, Adam K., Dong, Xiaoyang, Bury, Michael J., Romano, Joseph J., Mehlmann, John F., King, Bryan W., Erhard, Karl F., Hanning, Charles R., Lipshutz, David B., Desai, Biva M., Capriotti, Carol A., Schaeffer, Michelle C., Berger, Scott B., Mahajan, Mukesh K., Reilly, Michael A., Nagilla, Rakesh, Rivera, Elizabeth J., Sun, Helen H., Kenna, John K., Beal, Allison M., Ouellette, Michael T., Kelly, Mike, Stemp, Gillian, Convery, Máire A., Vossenkämper, Anna, MacDonald, Thomas T., Gough, Peter J., Bertin, John, Marquis, Robert W. · 2019 · Journal of Medicinal Chemistry
Cited by 63

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Abstract RIP2 kinase has been identified as a key signal transduction partner in the NOD2 pathway contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP2 kinase or its signaling partners on the NOD2 pathway that are suitable for advancement into the clinic have yet to be described. Herein, we report our discovery and profile of the prodrug clinical compound, inhibitor 3, currently in phase 1 clinical studies. Compound 3 potently binds to RIP2 kinase with good kinase specificity and has excellent activity in blocking many proinflammatory cytokine responses in vivo and in human IBD explant samples. The highly favorable physicochemical and ADMET properties of 3 combined with high potency led to a predicted low oral dose in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.9b00575

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 22

  1. Takeuchi, 2010, Pattern recognition receptors and inflammation, Cell, 140, 805, 10.1016/j.cell.2010.01.022 · DOI · Paper page
  2. Biswas, 2010, Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum, Proc. Natl. Acad. Sci. U. S. A., 107, 14739, 10.1073/pnas.1003363107 · DOI · Paper page
  3. Jamontt, 2013, Nucleotide-binding oligomerization domain 2 signaling promotes hyperresponsive macrophages and colitis in IL-10-deficient mice, J. Immunol., 190, 2948, 10.4049/jimmunol.1201332 · DOI
  4. Foley, 2013, OR3-001 – RIP2 kinase is activated in Blau Syndrome and IBD, Pediatric Rheumatology, 11, A3, 10.1186/1546-0096-11-S1-A3 · doi:10.1186/1546-0096-11-s1-a3
  5. Sfriso, 2012, Blau syndrome, clinical and genetic aspects, Autoimmun. Rev., 12, 44, 10.1016/j.autrev.2012.07.028 · DOI
  6. Ospelt, 2009, Expression, regulation, and signaling of the pattern-recognition receptor nucleotide-binding oligomerization domain 2 in rheumatoid arthritis synovial fibroblasts, Arthritis Rheum., 60, 355, 10.1002/art.24226 · DOI
  7. Rosenzweig, 2010, Nucleotide-binding oligomerization domain 2 and Toll-like receptor 2 function independently in a murine model of arthritis triggered by intraarticular peptidoglycan, Arthritis Rheum., 62, 1051, 10.1002/art.27335 · DOI
  8. Gatheral, 2012, A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses, PLoS One, 7, 10.1371/journal.pone.0042386 · DOI
  9. Schirbel, 2013, Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis, Gastroenterology, 144, 613, 10.1053/j.gastro.2012.11.005 · DOI · Paper page
  10. Hugot, 2001, Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease, Nature, 411, 599, 10.1038/35079107 · DOI · Paper page
  11. Haile, 2016, The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase, J. Med. Chem., 59, 4867, 10.1021/acs.jmedchem.6b00211 · DOI · Paper page
  12. Haile, 2018, Identification of quinoline-based RIP2 kinase inhibitors with an improved therapeutic index to the hERG ion channel, ACS Med. Chem. Lett., 9, 1039, 10.1021/acsmedchemlett.8b00344 · DOI
  13. Nachbur, 2015, A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production, Nat. Commun., 6, 6442, 10.1038/ncomms7442 · DOI · Paper page
  14. Canning, 2015, Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors, Chem. Biol., 22, 1174, 10.1016/j.chembiol.2015.07.017 · DOI
  15. Tigno-Aranjuez, 2014, In vivo inhibition of RIPK2 kinase alleviates inflammatory disease, J. Biol. Chem., 289, 29651, 10.1074/jbc.M114.591388 · DOI · Paper page
  16. Heimbach, 2003, Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs, Int. J. Pharm., 261, 81, 10.1016/S0378-5173(03)00287-4 · doi:10.1016/s0378-5173(03)00287-4
  17. Abbott, 2007, Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains, Mol. Cell. Biol., 27, 6012, 10.1128/MCB.00270-07 · DOI · Paper page
  18. Antoniou, 2016, The TNBS-induced colitis animal model: An overview, Annals of medicine and surgery (2012), 11, 9, 10.1016/j.amsu.2016.07.019 · DOI · Paper page
  19. Vossenkamper, 2014, A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease, Gastroenterology, 147, 172, 10.1053/j.gastro.2014.03.049 · DOI
  20. Fritz, 2005, Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists, Eur. J. Immunol., 35, 2459, 10.1002/eji.200526286 · DOI · Paper page
  21. van Heel, 2005, Synergistic enhancement of Toll-like receptor responses by NOD1 activation, Eur. J. Immunol., 35, 2471, 10.1002/eji.200526296 · DOI · Paper page
  22. Pashenkov, 2019, Synergistic interactions between NOD receptors and TLRs: Mechanisms and clinical implications, J. Leukocyte Biol., 105, 669, 10.1002/JLB.2RU0718-290R · DOI

Cited by

Metadata

Authors
Haile, P. A., Casillas, L. N., Votta, B. J., Wang, G. Z., Charnley, A. K., Dong, X., Bury, M. J., Romano, J. J., Mehlmann, J. F., King, B. W., Erhard, K. F., Hanning, C. R., Lipshutz, D. B., Desai, B. M., Capriotti, C. A., Schaeffer, M. C., Berger, S. B., Mahajan, M. K., Reilly, M. A., Nagilla, R., Rivera, E. J., Sun, H. H., Kenna, J. K., Beal, A. M., Ouellette, M. T., Kelly, M., Stemp, G., Convery, M. A., Vossenkämper, A., MacDonald, T. T., Gough, P. J., Bertin, J., & Marquis, R. W.
Venue
Journal of Medicinal Chemistry
Published
2019-07-02
Volume
62
Issue
14
Pages
6482-6494
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4252067953
Cited by
63
References
1
FWCI
2.43
Type
journal article
Language
en
Open access
hybrid
Funders
GlaxoSmithKline (NA)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.